ArticleClinical and experimental medicine2025
Integrative analysis identifies LHFPL6 as a CAF-specific prognostic biomarker in colorectal cancer.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Recent studies have emphasized the contributions of cancer-associated fibroblasts (CAFs) to cancer initiation, immune suppression, and treatment resistance. Advancing our molecular understanding of CAFs is therefore crucial to improve outcomes for colorectal cancer (CRC) patients. In this study, integrative analysis of single-cell RNA-sequencing data from GSE166555 and GSE144735 identified ten cellular subpopulations. Consensus clustering exhibited four distinct CAF subtypes, with the C4 subtype showing elevated expression of most CAF-specific genes, and predominant enrichment of stromal activation signatures. Functional enrichment analysis of C4-specific transcripts showed dominant enrichment in extracellular matrix (ECM) remodeling pathways. Univariate Cox regression analysis identified eight survival-critical genes, among which LHFPL6 demonstrated the highest specificity and sensitivity for discriminating C4 (AUC = 0.98). Multiple cohorts further confirmed that higher LHFPL6 expression was associated with worse survival outcomes across diverse clinical endpoints (all p < 0.05). Multivariate Cox regression analysis established LHFPL6 as an independent prognostic factor (HR = 5.889, p = 0.017). Additionally, LHFPL6 was predominantly expressed in fibroblasts and positively correlated with CAF scores. Co-expressed genes of LHFPL6 showed significant enrichment in ECM signatures and epithelial-mesenchymal transition (EMT) pathways. Functional experiments using CAF-tumor co-culture models demonstrated that LHFPL6 knockdown suppressed SW480 malignant behaviors, as evidenced by reduced proliferation, migration, and invasion. This study demonstrates that LHFPL6 serves as a promising prognostic biomarker and potential therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.